A Study of Tirzepatide (LY) Versus Placebo in Participants With ...
Have been diagnosed with type 2 diabetes mellitus (T2DM) and have been treated with insulin glargine (U100), once daily with or without metformin ≥3 months prior to screening visit. Have HbA1c between ≥% and ≤%. Have a stable weight (± 5%) for at least 3 months before screening.